Last reviewed · How we verify

Placebo + Tiotropium — Competitive Intelligence Brief

Placebo + Tiotropium (Placebo + Tiotropium) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting muscarinic antagonist (LAMA). Area: Respiratory / Pulmonology.

marketed Long-acting muscarinic antagonist (LAMA) M3 muscarinic receptor Respiratory / Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

Placebo + Tiotropium (Placebo + Tiotropium) — IRCCS Azienda Ospedaliero-Universitaria di Bologna. Tiotropium is a long-acting anticholinergic bronchodilator that blocks muscarinic receptors in airway smooth muscle to produce sustained bronchodilation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Placebo + Tiotropium TARGET Placebo + Tiotropium IRCCS Azienda Ospedaliero-Universitaria di Bologna marketed Long-acting muscarinic antagonist (LAMA) M3 muscarinic receptor
Solifenacin + Mirabegron Solifenacin + Mirabegron University of Aarhus marketed Antimuscarinic + Beta-3 adrenergic agonist combination M3 muscarinic receptor (solifenacin) and beta-3 adrenergic receptor (mirabegron)
Revefenacin 175 µg, Formoterol 20 µg Revefenacin 175 µg, Formoterol 20 µg University of Tennessee Graduate School of Medicine marketed Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) M3 muscarinic receptor; beta-2 adrenergic receptor
Atimos® Atimos® Chiesi Farmaceutici S.p.A. marketed Long-acting muscarinic antagonist (LAMA) M3 muscarinic receptor
umeclidinium bromide and vilanterol trifenatate umeclidinium bromide and vilanterol trifenatate Chiesi Farmaceutici S.p.A. marketed Long-acting muscarinic antagonist / Long-acting beta-2 agonist combination (LAMA/LABA) M3 muscarinic receptor and beta-2 adrenergic receptor
Solifenacin with vaginal estrogen cream Solifenacin with vaginal estrogen cream Mackay Memorial Hospital marketed Anticholinergic agent (solifenacin) + topical estrogen (vaginal cream) M3 muscarinic receptor (solifenacin); estrogen receptor (vaginal estrogen)
Vilanterol and Umeclidinium Bromide Vilanterol and Umeclidinium Bromide Samsung Medical Center marketed Long-acting beta-2 agonist / Long-acting muscarinic antagonist combination (LABA/LAMA) Beta-2 adrenergic receptor; M3 muscarinic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Long-acting muscarinic antagonist (LAMA) class)

  1. GlaxoSmithKline · 9 drugs in this class
  2. AstraZeneca · 3 drugs in this class
  3. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class
  4. Chiesi Farmaceutici S.p.A. · 1 drug in this class
  5. IRCCS Azienda Ospedaliero-Universitaria di Bologna · 1 drug in this class
  6. Lupin, Inc. · 1 drug in this class
  7. Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo + Tiotropium — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-tiotropium. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: